Experienced in Hypocomplementemic Urticarial Vasculitis

Dr. Arthur R. Mabaquiao

Rheumatology
Cabrillo Center For Rheumatic Disease Apc
San Diego, CA 
Offers Telehealth
Experienced in Hypocomplementemic Urticarial Vasculitis
Cabrillo Center For Rheumatic Disease Apc
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arthur Mabaquiao is a Rheumatologist in San Diego, California. Dr. Mabaquiao is rated as an Experienced provider by MediFind in the treatment of Hypocomplementemic Urticarial Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Microscopic Polyangiitis, Sjogren Syndrome, and Necrotizing Vasculitis.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Grossmont Hospital
Sharp Coronado Hospital And Hlthcr Ctr
Sharp Chula Vista Medical Center
El Centro Regional Medical Center
Sharp Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Moda Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

CABRILLO CENTER FOR RHEUMATIC DISEASE APC
San Diego, CA 92108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: June 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Soo I. Choi
Rheumatology
Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Soo I. Choi
Rheumatology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (1.9 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Soo Choi is a Rheumatologist in San Diego, California. Dr. Choi is rated as an Advanced provider by MediFind in the treatment of Hypocomplementemic Urticarial Vasculitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Scleroderma, Systemic Sclerosis (SSc), and Scleroma.

Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Mahmood P. Pazirandeh
Rheumatology
Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Mahmood P. Pazirandeh
Rheumatology

Morrison Multi-Specialties Companies Inc

San Diego, CA 
 (0.1 miles away)
619-287-9730
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mahmood Pazirandeh is a Rheumatologist in San Diego, California. Dr. Pazirandeh is rated as an Advanced provider by MediFind in the treatment of Hypocomplementemic Urticarial Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Juvenile Primary Osteoporosis.

Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Akther J. Kotha
Rheumatology
Experienced in Hypocomplementemic Urticarial Vasculitis
Dr. Akther J. Kotha
Rheumatology

Purushotham And Akther J Kotha M D Inc

8860 Ctr Dr, Suite 400, 
La Mesa, CA 
 (7.9 miles away)
619-229-1995
Languages Spoken:
English
See accepted insurances

Akther Kotha is a Rheumatologist in La Mesa, California. Dr. Kotha is rated as a Distinguished provider by MediFind in the treatment of Hypocomplementemic Urticarial Vasculitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, and Gerstmann-Straussler-Scheinker Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mabaquiao's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile